⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNTX News
Rein Therapeutics, Inc. Common Stock
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
globenewswire.com
RNTX
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
prnewswire.com
RNTX
Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions
globenewswire.com
RNTX
CORP
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
globenewswire.com
RNTX
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
globenewswire.com
RNTX
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
globenewswire.com
RNTX